Rain Therapeutics (RAIN) has released an update to notify the public and investors about listing compliance status.
The company has informed Nasdaq of the completion of a merger, requesting the suspension of trading of its shares from January 26, 2024, and the delisting and deregistration of shares from Nasdaq in accordance with the Securities Exchange Act of 1934. Additionally, the company plans to terminate the registration of the shares and suspend reporting obligations by filing the necessary forms with the SEC.
For further insights into RAIN stock, check out TipRanks’ Stock Analysis page.
